Background: Enterovirus (EV) and herpes simplex virus 1 and 2 (HSV1 and HSV2) are the main etiologic agents of central nervous system infections. Early laboratory confirmation of these infections is performed by viral culture of the cerebrospinal fluid (CSF), or the detection of specific antibodies in serum (e.g., HSV). The sensitivity of viral culture ranges from 65 to 75%, with a recovery time varying from 3 to 10 days. Serological tests are faster and easy to carry out, but they exhibit cross-reactivity between HSV1 and HSV2. Although molecular techniques are more sensitive (sensitivity >95%), they are more expensive and highly susceptible to cross-contamination.
Methods: A real-time RT-PCR for the detection of EV, HSV1, and HSV2 was compared with end-point nested PCR.
Results: We tested 87 CSF samples of patients with a clinical diagnosis of viral meningitis or encephalitis. Fourteen samples were found to be positive by RT-PCR, but only 8 were positive by end-point PCR. The RT-PCR showed a specificity range of 94-100%, the negative predictive value was 100%, and the positive predictive value was 62, 100, and 28% for HSV1, HSV2, and EV, respectively.
Conclusion: Real-time RT-PCR detected EV, HSV1, and HSV2 with a higher sensitivity and specificity than end-point nested RT-PCR.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1159/000480508 | DOI Listing |
J Family Med Prim Care
December 2024
Department of Microbiology, Rajendra Institute of Medical Sciences, Ranchi, Jharkhand, India.
Background: Herpes simplex encephalitis (HSE), caused by herpes simplex virus (HSV) is the most common cause of sporadic encephalitis that often presents as an emergency case of acute or sub-acute nature associated with poor prognosis. Early suspicion and prompt diagnostic testing with adequate antiviral therapy can only reduce morbidity and mortality associated with the disease. This study aims to evaluate the role of serological and molecular diagnosis of encephalitis caused by HSV 1 and 2 for timely detection of the disease.
View Article and Find Full Text PDFSex Transm Dis
February 2025
Quest Diagnostics Inc., San Juan Capistrano, CA.
Background: Approximately 2% of HerpeSelect herpes simples virus type 2 (HSV-2) IgG enzyme immunoassay (screen assay) sera-positive samples do not confirm using an HSV-2 IgG inhibition assay. Of these, roughly 1.33% are confirmed negative, and a small proportion (0.
View Article and Find Full Text PDFPLoS One
December 2024
Janssen Vaccines & Prevention, Leiden, The Netherlands.
Herpes Simplex virus (HSV) is the cause of genital herpes and no prophylactic treatment is currently available. Replication-incompetent adenoviral vectors are potent inducers of humoral and cellular immune responses in humans. We have designed an adenoviral vector type 35 (Ad35)-based vaccine encoding the HSV-2 major surface antigen gD2 (Ad35.
View Article and Find Full Text PDFIran J Microbiol
December 2024
Department of Microbiology, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.
Background And Objectives: Medicinal plants are the primary treatment for many infectious and non-infectious diseases. In this study, we evaluated the antiviral activity of against herpes simplex viruses 1 and 2, and compared it with the antiviral drug acyclovir.
Materials And Methods: In our experimental study, was dissolved in DMSO, then diluted in DMEM medium.
Front Oncol
December 2024
Western Michigan University Homer Stryker M.D. School of Medicine, Kalamazoo, MI, United States.
Background: Richter's transformation (RT) in chronic lymphocytic leukemia (CLL) is associated with poor prognosis and requires prompt modifications in patient care. CLL patients are susceptible to severe infections due to immune dysregulation induced by their malignancy and immunosuppressive therapies.
Case Presentation: We present a case of a 63-year-old man with CLL who previously achieved remission and presented with a right inguinal mass.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!